Drug discovery requires high-quality, high-throughput bioassays for lead identification and optimization. These assays are usually based on immortalized cell lines, which express the selected drug target either naturally or as a consequence of transfection with the cDNA encoding the target. Natural untransfected cell lines often fail to achieve the levels of expression required to provide assays of sufficient quality with a high enough signal-to-noise ratio. Unfortunately, the use of cDNA is increasingly restricted, as the sequences for more and more genes become subject to patent restrictions. To overcome these limitations, the authors demonstrate that engineered transcription factors with Cys 2 -His 2 zinc finger DNA-binding domains can be used to effectively activate an endogenous gene of interest without the use of isolated cDNA of the target gene. Using this approach, the authors have generated a cell line that provides a high-quality and pharmacologically validated G-protein-coupled receptor bioassay. In principle, this technology is applicable to any gene of pharmaceutical importance in any cell type. (Journal of Biomolecular Screening 2004:44-51) 
INTRODUCTION
T HE CURRENT DRUG DISCOVERY PROCESS relies on the availability of high-quality and high-throughput bioassays for the selected drug target. These bioassays allow assignment of the pharmacological parameters that guide medicinal chemists in lead compound selection and the subsequent evolution of these leads into clinical candidates. An ideal drug discovery bioassay is one that is economic, robust, and amenable to high-throughput screening (HTS) and provides high signal-to-noise ratios and compound activity estimates that are preferably indistinguishable from those obtained in fresh human tissue.
The difficulties and restrictions associated with developing assays from untransfected natural cell lines that already express a target are well documented. 1 For example, the cells may not be pre-pared at the scale necessary for HTS, and suitable negative control cell lines can be difficult to find. Often, low or undetectable levels of target gene expression make it difficult to identify suitable immortalized cells that can provide the necessary signal for a highquality assay. Obtaining high expression through transfection of the target cDNA into cell lines suitable for drug screening is becoming increasingly hampered by intellectual property restrictions on the use of specific cDNAs. 2 Moreover, such transfected cell lines may not provide meaningful pharmacological data, as the target protein may not be expressed to physiologically relevant levels, forms, or locations, causing misleading pharmacological behavior due to overexpression. 3 Furthermore, the contribution of protein isoforms produced by alternative mRNA splicing is lost using cDNA-based approaches. The use of engineered transcription factors to activate the expression of endogenous genes offers a solution to these problems as it can be applied to generating cell lines suitable for bioassays without the use of target cDNA.
Engineered Cys 2 -His 2 zinc finger proteins (ZFPs) that recognize novel DNA sequences can be used to create artificial transcription factors (reviewed in [4] [5] [6] [7] [8] . A ZFP contains a tandem array of zinc finger motifs (each consisting of 2 antiparallel β-strands followed by an α-helix structure), with each individual zinc finger motif recognizing a 3-to 4-bp DNA sequence. [9] [10] [11] [12] A ZFP with 3 such zinc finger motifs, such as Zif268 (a naturally occurring ZFP), recognizes a 9-bp DNA sequence. The modular interactions between zinc fingers and DNA allow for rational design and selection of artificial transcriptional factors that will bind specifically to targeted DNA sequences. [13] [14] [15] By designing the ZFPs to bind to specific sequences in a promoter and linking them to a transcriptional activation or repression domain, the expression of a chosen endogenous gene and its natural array of splice variants can be activated or repressed (Fig. 1 ). This technology has been applied successfully for the regulation of a variety of genes such as erythropoietin, 16 MDR1, 17 ErbB2 and ErbB3, 18 VEGF, 19, 20 PPAR-γ, 21 and IGF2. 22 The activation of specific genes at their chromosomal locus by ZFP technology does not use isolated cDNA encoding the gene target, thereby providing a potential "workaround" solution to cDNA patents, and should offer a more physiologically relevant expression system (Morton et al., manuscript in preparation).
To explore the utility of ZFPs in providing a good-quality, validated bioassay suitable for drug discovery, we have engineered a cell line to functionally upregulate the expression of the cholecystokinin (CCK) B receptor or gastrin receptor (CCKBR, also known as CCK2R), a widely investigated and recently patented G-protein-coupled receptor. 23, 24 
MATERIALS AND METHODS

Mapping the DNaseI hypersensitive site of the CCKBR gene
Accessible regions within chromatin were identified using DNaseI hypersensitive site mapping, as previously described. 25 The genomic DNA isolated from DNaseI-treated cells was digested with BglII and samples analyzed using Southern blotting. The sequence of the DNA probe used for Southern hybridization corresponds to region +271 to +549, relative to the transcription start site of the human CCKBR gene. The transcription start site is designated based on the longest published mRNA sequence (Genbank accession XM_044494). This site is also consistent with the transcription start site experimentally determined for mouse CCKBR. 26 
Assembly and construction of ZFPs
Sequences encoding the ZFP domains were assembled, cloned using PCR, and their binding affinity measured using gel-shift assays, as described previously. 16, 20 The ZFP domains were fused with the herpes simplex virus VP16 activation domain (amino acid residues 413-490, Genbank accession P06492). 27 All ZFP-VP16 fusion constructs also contained an N-terminal nuclear localization signal (Pro-Lys-Lys-Lys-Arg-Lys-Val) from SV40 large T antigen and a C-terminal FLAG epitope tag (Asp-Tyr-Lys-Asp-Asp-Asp-Asp-Lys). The ZFPs were cloned into the pcDNA3 mammalian expression vector (Invitrogen, San Diego, CA) and their expression driven by a cytomegalovirus promoter.
Assay for endogenous CCKBR gene activation by ZFP using transient transfection
HEK293 cells (ATCC, Manassas, VA) were grown in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum (Invitrogen, Carlsbad, CA) in a 5% CO 2 incubator at 37°C. The cells were seeded in 24-well plates at a density of 160,000 cells/well 24 h before transfection. Plasmids encoding ZFP-VP16 fusions were transfected into the cells using LipofectAMINE 2000 reagent (Invitrogen, San Diego, CA) according to the manufacturer's recommendations. Then, 48 h following transfection, the cells were harvested and assayed for ZFPprotein production using Western blotting and the expression of CCKBR mRNA by real-time quantitative reverse transcriptase PCR (RT-PCR) using Taqman chemistry. For Western blotting, lysates prepared from the same number of cells were analyzed using sodium dodecyl sulfate (SDS) polyacrylamide gel electrophoresis, 28 and FLAG-tagged ZFP protein was detected using a monoclonal M2 anti-FLAG antibody (Sigma-Aldrich) and visualized using enhanced chemiluminescence (Amersham Biosciences, Piscataway, NJ). For quantitative RT-PCR analysis, total RNA was prepared using the RNeasy kits with in-column DNase treatment (Qiagen, Valencia, CA). Taqman RT-PCR was performed on an ABI 7700 machine (PerkinElmer Life Sciences, Boston), and mRNA levels were normalized to glyceraldehyde-3phosphate dehydrogenase levels, as described previously. 19 The primers used for quantitative RT-PCR analysis of CCKBR gene expression were 5′-CTTTGGCACCGTCATCTGCA-3′ and 5′-GTACCGCTCCAG TGCGATG-3′. The Taqman probe used was 5′-FAM-TCCTACCTCATGGGGGTGTCTGTGA-TAMRA-3′.
Generation of stable inducible cell lines
The parental T-REx-293 cell line (Invitrogen, San Diego) was cultured in Dulbeccos modified Eagles medium supplemented with 10% fetal bovine serum in a 5% CO 2 incubator at 37°C. To generate stable tetracycline-inducible cell lines expressing the ZFP+53-VP16 transcription factor, the coding region from the pCMV-ZFP+53-VP16 vector was subcloned into pcDNA4/TO (Invitrogen, San Diego). The resulting pTO-ZFP+53-VP16 con- struct was transfected into the T-REx-293 cell line using LipofectAMINE 2000 (Invitrogen, San Diego). After 2 weeks of selection in culture medium containing 400 µg/mL Zeocin (Invitrogen, San Diego), drug-resistant stable clones were isolated and analyzed for ZFP+53-VP16 production (by Western blotting) as well as CCKBR mRNA expression (by quantitative RT-PCR) upon induction with 2 ng/mL doxycycline (a tetracycline analog, Sigma-Aldrich) for 48 h. The clones with the best induction profiles were chosen for functional studies.
Calcium-flux measurement
Cells were seeded into black-wall 96-well plates (Packard Bio-Science) at 30,000 cells/well and grown for 2 days in culture medium in the absence or presence of 2 ng/mL doxycycline. On the day of the experiment, the media were removed and the cells incubated with 100 µL of culture medium containing Fluo-3 AM (4 µM), pluronic F127 (0.04% in DMSO, both from Molecular Probes, Eugene, OR), and 2.5 mM probenecid (Sigma-Aldrich) for 1 h at room temperature. The intracellular Ca 2+ flux was assayed using a fluorescent imaging plate reader (FLIPR; Molecular Devices, Menlo Park, CA) 29 to simultaneously monitor Fluo-3 AM fluorescence in all wells (λ excitation = 488 nm, λ emission = 540 nm). Cells were challenged with agonist CCK-8S (Phoenix Pharmaceuticals, Inc., Belmont, CA) at 10 sec, and the fluorescence intensity was captured every 1 sec for 1 min. For antagonist studies, the cells were preincubated with the test compounds for 20 min prior to calcium-flux measurement.
Data analysis
The Z′ factor and signal-to-noise (S/N) ratio in the HTS were calculated based on the equations as published by Zhang et al.: 30 Z′ factor = 1 -3 × (SD 2 + SD 1 )/|M 2 
where M 2 and M 1 represent the means of the maximal fluorescence value (in the absence of antagonists) and minimal (background) fluorescence signals, respectively, and SD 2 and SD 1 represent the standard deviations of the maximal and minimal signals.
RESULTS AND DISCUSSION
Mapping DNaseI-accessible regions in the CCKBR promoter
Previous studies have indicated that the activity of ZFP transcription factors can be increased by targeting the proteins to accessible regions within the locus of interest. 16, 19 To map accessible regions in the CCKBR promoter, we carried out the DNaseI hypersensitive site analysis in HEK293 cells, a human embryonic kidney cell line that is well established as being suitable for bioassay work but with undetectable basal CCKBR gene activity. As illus-trated in Figure 2 , 2 DNaseI hypersensitive regions were observed within this locus. DNaseI hypersensitive region I was located approximately between bases -30 and +170 (relative to the start site of transcription), and DNaseI hypersensitive region II was located approximately between bases -500 and -300. Both DNaseI hypersensitive regions contain sequences that were conserved between human and mouse, suggesting important regulatory roles for these regions. A similar pattern of DNaseI accessibility at this locus was observed in the cell line H510, a small cell lung carcinoma line with natural, albeit low, expression of the CCKBR gene 31 (data not shown).
Engineered ZFP transcription factor
We selected several 9-bp target sequences for ZFP recognition from within and around the DNaseI-accessible regions and designed ZFPs containing 3 zinc finger motifs to bind specifically and with subnanomolar affinity to these selected target sequences. For example, the engineered ZFP, designated ZFP+53, was targeted to DNaseI hypersensitive region I at position +53 relative to the transcription start site (Fig. 2) . For CCKBR gene activation, we linked the engineered ZFP DNA-binding domains to the VP16 transcriptional activation domain. 27 The complete protein sequence of the engineered transcription factor, designated ZFP+53-VP16, is shown in Figure 3A . The amino acid residues located at positions -1, 2, 3, and 6 of each of the recognition helixes have been shown to be the critical residues involved in contacting the DNA base pairs [9] [10] [11] [12] and are indicated in the figure.
Functional CCKBR activation mediated by the ZFPs
We first tested the ability of the engineered transcription factor to activate endogenous CCKBR gene expression in HEK293 cells by transient transfection. As demonstrated in Figure 3B ,C, introduction of ZFP+53-VP16 protein resulted in an increase in the expression of the CCKBR gene, as determined by real-time quantitative PCR (by about 200-fold).
We then established a stable inducible cell line expressing ZFP+53-VP16. The ZFP was placed under the control of a tetracycline-regulatable promoter and transfected into the T-REx-293 cell line (which stably expresses the Tet-repressor). Singlecell-derived colonies were picked after 2 weeks in drug selection, and several were chosen for further studies. One such line, named HEKZFP, is shown in Figure 4 . As determined by Western blotting using an antibody against the FLAG-epitope tag carried by the ZFPs (Fig. 4A inset) , the cell line produced ZFP protein only when doxycycline was present in the culture medium, and the amount of ZFP produced was doxycycline concentration dependent. CCKBR mRNA was also activated in a doxycycline concentrationdependent manner (Fig. 4A) . The level of CCKBR mRNA produced in the stable HEKZFP line with 2 ng/mL of doxycycline was approximately 5-fold higher than the levels observed in HEK293 cells that were transiently transfected with a plasmid expressing the same ZFP (data not shown).
To determine whether the elevated levels of CCKBR mRNA observed in response to ZFP induction resulted in the production of functional CCKBR protein, an intracellular calcium-flux assay was performed. As demonstrated in Figure 4B , the sulfated cholecystokinin octapeptide (CCK-8S) at 10 nM triggered a rapid and transient increase in fluorescence intensity representing a transient increase in intracellular Ca 2+ concentrations. This agonistdependent calcium-flux response was observed only in the doxycycline-induced HEKZFP cell line. No calcium-flux was observed in the absence of either the agonist or doxycycline. The magnitude of the calcium-flux response observed was dependent on the concentration of doxycycline in the culture medium (Fig.  4C) . Indeed, the activity data correlated strikingly with the doxycycline-dependent levels of ZFP production and concomitant CCKBR mRNA activation (Fig. 4A) . These results demonstrate that functional CCKBR protein is produced in the induced binding assays, we have determined the number of apparent receptors on the cell membrane to be approximately 100,000 per cell upon induction (B max = 0.16 ± 0.01 fMol/1000 cells with 1 ng/mL of doxycycline) (Morton et al., manuscript in preparation). We further characterized the pharmacological properties of the induced HEKZFP system using peptide ligands with known profiles in calcium-flux assays. As shown in Figure 5 , the induced HEKZFP cells displayed a high-affinity response to both the cholecystokinin octapeptide (CCK-8S) and tetrapeptide (CCK-4S) as well as gastrin (gastrin-17), with LogEC 50 values of -9.1 ± 0.1, -8.3 ± 0.1, and -8.95 ± 0.04, respectively. These values are comparable to those generated using CCKBR cDNA 32, 33 and are consistent with the selective activation of CCKBR and not the closely related CCKAR receptor. Unrelated peptide ligands for other G-protein-coupled receptors, such as neuromedin and melanin-concentrating hormone, did not induce any calcium-flux response in this cell line (data not shown). Therefore, the HEKZFP cell line demonstrated specificity for the CCKBR receptor, allowing cell-based screening for CCKBR selective ligands.
Use of the HEKZFP cell line in HTS
To demonstrate the practical use of the HEKZFP cell line in HTS, we performed an antagonist screen of a test library of nonpeptide small-molecule compounds. The screen was conducted in 96-well plates using HEKZFP cells induced with 2 ng/ mL of doxycycline for 2 days. The CCK-8S-induced calcium-flux was used as the endpoint. Cells without doxycycline treatment (uninduced) served as a convenient and isogenic negative control. The test compounds (at concentrations of 1 µM, 10 µM, and 100 µM) were incubated with the cells for 20 min before the addition of agonist CCK-8S. Overall, a Z′ factor of 0.65 was obtained in the screen with an S/N of 20, demonstrating the high quality of this bioassay. 34 We obtained several confirmed hits in our screen. The structures and pK i values of the hits are shown in Figure 6 . Compared to the known high-affinity CCKBR-selective antagonists, such as RP-73870, 35 L-365260, 36 YM-022, 37 and LY-288513, 37 these compounds have considerably lower affinities in our assays (Fig. 6B ). Nevertheless, these compounds have shared structural features that are consistent with the established pharmacophores for CCKBR-specific antagonists (Fig. 6A ). This study validated the performance of the CCKBR-specific HEKZFP cell line in an HTS setting and provided a core structure from which highaffinity antagonists could be obtained through further structure-activity relationship studies.
In conclusion, cell lines generated using the engineered zinc finger transcription factor technology provide a high-quality bioassay system with a high signal-to-noise ratio without the use of cDNA. Given the large number of genes that have been successfully regulated by engineered ZFP transcription factors in many different cell types, this technology is applicable, in principle, to any gene of therapeutic importance in any cell type. Results obtained from a high-throughput small-molecule screen conducted using the HEKZFP bioassay system. The screen was conducted in 96-well plates using HEKZFP cells induced with 2 ng/mL of doxycycline for 2 days. Test compounds were preincubated with the cells for 20 min before measurement of calcium-flux initiated by the injection of 10 nM of CCK-8S. (A) The chemical structures of the potential lead compounds and several known CCKBR-selective antagonists. A box drawn on each of these structures indicates a conserved chemical structure shared by all of these compounds. (B) The concentration-response curves of the potential lead compounds. The data were analyzed using unconstrained nonlinear regression analysis using the GraphPad Prism software (GraphPad Software, Inc.). The K i values were calculated from the midpoint locations (IC 50 ) using the equation K i = IC 50 /(1 + [A]/EC 50 ), where [A] is the agonist concentration used in the experiment (10 nM) and EC 50 is the EC 50 of the agonist alone (0.8 nM), according to Cheng and Prusoff, 38 and are given in each graph separately.
